ABSTRACT
Transfusion of allogeneic donor leukocytes present in cellular blood components results in a number of both proven and perceived adverse effects in recipients. Over the last decade, a greater understanding of these possible adverse effects has been the impetus for improving methods of leukoreduction. Advances in technology have allowed more widespread use of leukoreduced components and have prompted active investigation into the potential benefits of these products. This chapter will describe the methods, indications for, and efficacy of leukoreduction.
